PP
ACET icon

Paloma Partners’s Adicet Bio ACET Stock Holding History

Paloma Partners’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,939
Closed -$76.3K – 1104
2024
Q2 		$76.3K Buy
+3,939
New +$106K ﹤0.01% 1107
2020
Q3 		– Sell
-757
Closed -$182K – 2016
2020
Q2 		$182K Buy
+757
New +$149K ﹤0.01% 1733

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Paloma Partners's ACET Position: Q3 2024 in Review

Paloma Partners sold out of Adicet Bio (ACET) in Q3 2024, closing a stake of 3,939 shares — an estimated $76.3K sold.

Paloma Partners first reported a position in ACET in Q2 2020 and held it in 2 quarters. The position peaked at $182K in Q2 2020. 64 funds tracked by Wall St. Rank hold ACET as of Q3 2024.

  • Paloma Partners reported no remaining Adicet Bio position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 3,939 Adicet Bio shares in Q3 2024, an estimated $76.3K.
  • Paloma Partners first reported a position in Adicet Bio in Q2 2020 and held it in 2 quarters.
  • Paloma Partners's Adicet Bio position peaked at $182K in Q2 2020.
  • 64 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.